Efficacy of baricitinib in the treatment of Systemic lupus erythematosus (SLE): A Systemic review and meta-analysis

Zaidi, Syed Muhammad Mehdi; Ahmed Fatmi, Syed Ashad; Ashraf, Muhammad Hasan; Waheed, Faiq; Jawwad, Mohammad; Hai, Ahmed Abdul; Ahmed, Syed Arsalan

doi:10.1016/j.heliyon.2023.e22643

Heliyon

2023

DOI: 10.1016/j.heliyon.2023.e22643

|View full text |Cite

Efficacy of baricitinib in the treatment of Systemic lupus erythematosus (SLE): A Systemic review and meta-analysis

Syed Muhammad Mehdi Zaidi,

Syed Ashad Ahmed Fatmi,

Muhammad Hasan Ashraf

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mastitis granulomatosa con buena respuesta a baricitinib

Pimentel León,

Núñez Rodríguez,

Rebollar Vega

2025

Revista de Senología y Patología Mamaria

View full text Add to dashboard Cite

Mastitis granulomatosa con buena respuesta a baricitinib

Pimentel León,

Núñez Rodríguez,

Rebollar Vega

2025

Revista de Senología y Patología Mamaria

View full text Add to dashboard Cite

Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systemic review and meta-analysis

Abbasi,

Irfan,

Zaidi

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatohepatitis (MASH) affects nearly 38% of the population, potentially progressing to cirrhosis and cancer. Lifestyle changes remain the cornerstone of management, but adherence is challenging, prompting the exploration of therapeutic options. Resmetirom, targeting thyroid hormone receptors, regulates liver enzymes and fat metabolism, showing potential as a treatment for MASH. This systematic review and meta-analysis evaluates the safety of resmetirom in MASH patients. Three randomized controlled trials with adult participants were analyzed, sourced from PubMed and the Cochrane Library until April 2024. Participants received either resmetirom or placebo, and data on adverse effects and efficacy outcomes were extracted. Statistical analyses, including risk ratios (RRs) and confidence intervals (CI), were performed using Review Manager (version 5.4.1) with a random-effects model. The pooled RR for serious adverse events was 0.85 (95% CI: 0.63–1.14; P = 0.28), indicating no significant difference. However, diarrhea (RR = 1.82, 95% CI: 1.41–2.35; P < 0.001) and nausea (RR = 1.73, 95% CI: 1.31–2.28; P < 0.001) showed higher incidence. No significant differences were found for fatigue (RR = 1.19, 95% CI: 0.77–1.84; P = 0.43) or urinary tract infections (RR = 1.07, 95% CI: 0.76–1.52; P = 0.69). Liver fat content, lipid profiles, and liver enzymes also showed significant improvement in the resmetirom group. Low heterogeneity across most outcomes indicated consistent findings among the studies. While resmetirom demonstrates efficacy in improving lipid and liver profiles, its increased risk of diarrhea and nausea should be considered in therapeutic decisions.

show abstract

Outlook of the jakinibs in systemic lupus erythematous after baricitinib failed

Mok

2024

Int J of Rheum Dis

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Efficacy of baricitinib in the treatment of Systemic lupus erythematosus (SLE): A Systemic review and meta-analysis

Cited by 3 publications

References 13 publications

Mastitis granulomatosa con buena respuesta a baricitinib

Mastitis granulomatosa con buena respuesta a baricitinib

Safety and efficacy of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a systemic review and meta-analysis

Outlook of the jakinibs in systemic lupus erythematous after baricitinib failed

Contact Info

Product

Resources

About